Biota will need possibly over $100m to fund phase III trials. Doubt they can self fund. They will need to preset the data to potential suitors who will be well aware of issues with competitor drugs. Limited side effects is crucial, as is efficacy.
On the surface, the announcement is great. But it will ultimately come down to large pharma's view of the data.
other players, page-3
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)